Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 5:38 PM
Ignite Modification Date:
2025-12-25 @ 3:08 PM
NCT ID:
NCT01665768
Group ID:
EG000
Title:
Everolimus and Rituximab
Description:
Everolimus daily for one year and IV rituximab four times during that year.
Everolimus: The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL. Previously the study allowed for starting doses of 5mg and 10mg; the starting dose was reduced in subsequent amendments due to a high incidence of dose reductions. 2.5mg was the most frequent daily dose for all patients, and the entire population was analyzed as one arm.
Rituximab: 375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
13
Serious Number At Risk:
49
Other Number Affected:
47
Other Number At Risk:
49
Study:
NCT01665768
Results Section:
NCT01665768
Adverse Events Module:
NCT01665768